期刊文献+

血清TK1在不同分子分型、病理分期乳腺癌中的表达及其临床意义 被引量:4

Expression of Serum TK1 in Breast Cancer with Different Molecular Typing and Pathological Stages and Its Clinical Significance
下载PDF
导出
摘要 目的:探究血清TK1在不同分子分型、病理分期乳腺癌中的表达及其临床意义。方法:选取某院头颈乳腺外科2017年1月~2018年6月收治的乳腺肿瘤患者160例,收集160例患者血清样本,其中乳腺良性肿瘤40例,乳腺癌120例。另选正常对照组患者40例,比较不同病理参数下TK1水平差异,分析血清TK1在不同分子分型、病理分期乳腺癌中的表达。结果:正常对照组和乳腺良性肿瘤组血清TK1相比无显著统计学意义(P>0.05);乳腺癌各期血清TK1水平均较乳腺良性肿瘤组高(P<0.05);乳腺癌Ⅱ期及Ⅲ期患者血清TK1水平高于0期、Ⅰ期患者(P<0.05);血清TK1水平与乳腺癌患者年龄、HER-2水平无显著统计学意义(P>0.05),与有无淋巴结转移差异具有统计学意义(P<0.05);TK1在乳腺癌各分子分型中的阳性表达与淋巴结转移情况具有相关性(P<0.05)。结论:血清TK1与乳腺癌的发生发展具有密切联系,对乳腺癌预后评估和病情监测有重要价值。 Objective:To investigate the expression of serum TK1 in breast cancer with different molecular typing and pathological stages and its clinical significance. Methods: 160 patients with breast tumors admitted to the department of head and neck mammary surgery of a hospital from January 2017 to June 2018 were selected. Serum samples were collected from 160 patients, including 40 cases of benign breast tumors and 120 cases of breast cancer. Another 40 cases of normal control group were selected. Compared the difference of TK1 level under different pathological parameters and analyzed the expression of TK1 in breast cancer with different molecular typing and pathological stages. Results: There was no significant difference in serum TK1 between normal control group and benign breast cancer group(P>0.05). The serum TK1 level of breast cancer patients in different stages was higher than that of benign breast cancer patients(P<0.05). The serum TK1 level of breast cancer patients in stage Ⅱ and Ⅲ was higher than that of patients in stage 0 and Ⅰ(P<0.05). There was no significant difference between serum TK1 level and breast cancer patients’ age and HER-2 level(P>0.05), but had significant difference with lymph node metastasis(P<0.05). The positive expression of TK1 in breast cancer molecular typing was correlated with lymph node metastasis(P<0.05). Conclusion: Serum TK1 is closely related to the occurrence and development of breast cancer, and has important value in prognosis evaluation and disease monitoring of breast cancer.
作者 欧林洋 李敏 黄仁峰 杨传盛 Ou Linyang(Department of Head and Neck Mammary Surgery, Shaoguan Northern Guangdong People's Hospital, Guangdong Province, Shaoguan 512000)
出处 《数理医药学杂志》 2019年第7期949-951,共3页 Journal of Mathematical Medicine
基金 韶关市医药卫生科研计划项目,Y17042
关键词 血清TK1 病理分期 乳腺癌 serum TK1 pathological stage breast cancer
  • 相关文献

参考文献9

二级参考文献59

  • 1彭萍,杨冬梓,郑澄宇,赖宝玲,罗璐,刘惠芬,何钻玉.促性腺激素释放激素激动剂在化疗患者卵巢功能保护中应用的研究进展[J].中华妇产科杂志,2006,41(2):139-141. 被引量:15
  • 2He E,Xu XH,Guan H,et al. Thymidine kinase 1 is a potential marker for prognosis and monit-oring the response to treatment of patients with breas-lung and esophageal cancer and non-Hodgkin' s lymphoma [ J ]. Nucleosides Nucleotides Nucleic Acids ,2010,29 (4 - 6 ) : 352 - 358.
  • 3Lindsey A T, Freddie B, Rebecca L, et al. Global Cancer Statistics [J]. CA Cancer J Clin,2015,65(2):87-108.
  • 4Shapiro C L, Recht A. Side effects of adjuvant treatment of breast cancer[J]. N Eng J Med,2001,344(26):1997-2008.
  • 5Sukumvanich P, Case L D, Van Zee K, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: A prospective study[J]. Cancer,2010,116(13):3102- 3111.
  • 6Schally A V, Nair R M, Redding T W, et al. Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalamic[J]. J Biol Chem,1971, 246(23):7230- 7236.
  • 7Nicholson R I, Walker K J. Preclinical studies and antitumor mechanism of action of LHRH analogues[J]. Cancer Treat Res,1988, 39: 1-23.
  • 8Oktay K, Briggs D, Gosden R G. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follic es[J]. J C nEndocr no Metab,1997,82(11):3748-3751.
  • 9Bines J, Oleske D M, Cobleigh M A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer[J]. J C nOnco ,1996,14(5):1718-1729.
  • 10Di Cosimo S, Alimonti A, Ferretti G, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer [J]. Ann Oncol,2004,15(7):1065-1071.

共引文献1216

同被引文献43

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部